- Page 1:
Autologous Bone Marrow Transplantat
- Page 5 and 6:
CONTENTS nviAum TMLHTA'I OTT! 7 A l
- Page 7 and 8:
AUTOLOGOUS BONE MARROW TRANSPLANTAT
- Page 9 and 10:
TREATMENT OF NONSMALL CELL LUNG CAN
- Page 11:
SUMMARY OF THE NON HODGKIN LYMPHOMA
- Page 15:
Session I: Leukemia
- Page 18 and 19:
TRIAL PROGRESS The trial opened in
- Page 20 and 21:
Table 1. Achievement of Second Remi
- Page 22 and 23:
ALLOGENEIC VERSUS AUTOLOGOUS BONE M
- Page 24 and 25:
pts). The other 56 pts are too earl
- Page 26 and 27:
Figure 1 EORTC-GIMEMA AML 8 A EORTC
- Page 28 and 29:
PATIENTS AND METHODS Patients The B
- Page 30 and 31:
Thus, as the results of some ongoin
- Page 32 and 33:
COMPARISON OF INTENSIVE CONSOLIDATI
- Page 34 and 35:
over, 13 pts who had received ICC1
- Page 37:
Session II: Future Directions
- Page 40 and 41:
in a previous report 3 . Analysis a
- Page 42 and 43:
Engraftment of granulocyte, monocyt
- Page 44 and 45:
0.2 - 0.1 - ABMT with mAb purging f
- Page 46 and 47:
ENHANCED REGENERATION OF NATURAL KI
- Page 48 and 49:
RESULTS The in vivo immune effects
- Page 50 and 51:
16. Rizzoli V, Mangoni L, Carlo-Ste
- Page 52 and 53:
hydroperoxycyclophosphamide (4HC)-t
- Page 54 and 55:
survival in patients undergoing ABM
- Page 56 and 57:
IMMUNOTHERAPY OF AML AFTER ABMT - S
- Page 58 and 59:
Otherwise toxicity was mild to mode
- Page 60 and 61:
Therapy. Amsterdam Elsevier 1987;89
- Page 62 and 63:
200 IL6 in serum 44 SIXTH INTERNATI
- Page 64 and 65:
sodes), fewer days of i.v. antibiot
- Page 67:
Session III: Myeloma
- Page 70 and 71:
trary, in case of adequate collecti
- Page 72 and 73:
tion is considered, and all the mor
- Page 74 and 75:
Table 3: Cost effectiveness of high
- Page 77:
Session W: Lymphoma
- Page 80 and 81:
METHODS Selection of patients and t
- Page 82 and 83:
marrow treatment. Am J Med 85:829,1
- Page 84 and 85:
HIGH DOSE THERAPY WITH HEMATOPOIETI
- Page 86 and 87:
in TC 19 medium (Flobio), with an h
- Page 88 and 89:
progression for a long time after A
- Page 90 and 91:
Table 2. STATUS AT GRAFT Remission
- Page 92 and 93:
IL Figura 3 70 SIXTH INTERNATIONAL
- Page 94 and 95:
( 5 ) lowed by ABMT than refractory
- Page 96 and 97:
74 Figure 4 Low grade lymphoma - pr
- Page 98 and 99:
(range 15-55); 68 males and 32 fema
- Page 100 and 101:
our experience, this has a seven-ye
- Page 102 and 103:
30. Colombat P, Gorin NC, Lemonnier
- Page 104 and 105:
82 OVERALL SURUIWL from ABUT (accor
- Page 107 and 108:
PROGNOSTIC FACTORS IN ADVANCED STAG
- Page 109 and 110:
REFERENCES 1. Chopra R, Mc Millan A
- Page 111 and 112:
lished data to attempt to assess th
- Page 113 and 114:
1992;10:175-7. 3. McMillan A, Golds
- Page 115 and 116:
B. DAILY DAY AGENT DOSE -7 -6 -5 -4
- Page 117 and 118:
cohort with HR treated with BEC-2 i
- Page 119 and 120:
p R 0 P O R T I 0 N 1 0.9 0.8 0.7 0
- Page 121 and 122:
TABLE 3. TOXICITY BEC TAVe TMJ as 2
- Page 123 and 124:
ies. 10 Longer blood half-lives hav
- Page 125 and 126:
agents have been developed cautious
- Page 127 and 128:
Table 1. Radioisotopes for RIT. Pur
- Page 129 and 130: The treatment criterion in this stu
- Page 131 and 132: more than 80% of the cases. Patient
- Page 133 and 134: Disease Free Survival 800 Time •
- Page 135: Session VI: Breast Cancer
- Page 138 and 139: achieved a complete remission survi
- Page 140 and 141: acil, vincristine, prednisone (CMFV
- Page 142 and 143: t: 3 en a in S « J •S •> c ai
- Page 144 and 145: LONG TERM FOLLOW UP OF POOR PROGNOS
- Page 146 and 147: tors both for progression-free surv
- Page 148 and 149: 222 INDUCTION PHASE ESTROGEN RECEPT
- Page 150 and 151: THE PHARMACOLOGY OF INTENSIVE CYCLO
- Page 152 and 153: PK VARIABILITY OF CPA/CDDP/BCNU Whe
- Page 154 and 155: 5. Groshow LB, Piantadosi S, Santos
- Page 157 and 158: - Tn'üTiifi'.m'jii.'yjKJiHtyiwiT T
- Page 159 and 160: normal CD34+ progenitor cells
- Page 161 and 162: sequence analysis of the human haem
- Page 163 and 164: Bielefeld, FRG) or control medium w
- Page 165 and 166: 3. Koeffler HP, and Golde DW: Chron
- Page 167 and 168: ply infected with supernatants from
- Page 169 and 170: controls must be carefully matched
- Page 171 and 172: Fig. IB: GPI isozyme analysis of 2
- Page 173 and 174: PROCESSING OF STEM CELLS FOR TRANSP
- Page 175 and 176: in progress using marker genes to l
- Page 177 and 178: Table 1. Factors Affecting Quality
- Page 179: Figure 2 .2 A Refractory/Relapsed L
- Page 184 and 185: completion of conventional salvage
- Page 186 and 187: treatment of poor risk non seminoma
- Page 188 and 189: TOXICITY Mean time to PMN count >50
- Page 190 and 191: TABLE 1: PATIENTS' CHARACTERISTICS
- Page 193 and 194: INTENSIVE COMBINED MODALITY THERAPY
- Page 195 and 196: chest and upper abdominal computeri
- Page 197 and 198: nosed by fine needle aspirate, pres
- Page 199 and 200: Soc, Series A. 1972; 135:185-198. 8
- Page 201 and 202: Induction Chemotherapy to Maximum R
- Page 203 and 204: Table 1: Characteristics of 30 Pati
- Page 205 and 206: Table 3: SITES OF RELAPSE N Relapse
- Page 207 and 208: marrow support with or without peri
- Page 209 and 210: Table 4. Resulte of VP-16/Platlnol
- Page 211 and 212: HIGH DOSE RADIOTHERAPY FOR NON-SMAL
- Page 213: mens that incorporate biological pr
- Page 217 and 218: CONVENTIONAL TREATMENT RESULTS IN E
- Page 219 and 220: suits of treatment remain unsatisfa
- Page 221 and 222: platelet support. This drug combina
- Page 223 and 224: Table 1. Operative Staging of Ovari
- Page 225 and 226: Table 3. Response Complete response
- Page 227 and 228: Higher dose carboplatin with marrow
- Page 229 and 230: leukemia, Hodgkin's and non-Hodgkin
- Page 231:
transplantation for refractory soli
- Page 235 and 236:
HIGH DOSE CHEMOTHERAPY AND AUTOLOGO
- Page 237 and 238:
graphies are given in Table 1. In a
- Page 239 and 240:
VP-16 CBDCA CYTOXAN DAY SCHEMA FOR
- Page 241:
Session XI: CML
- Page 244 and 245:
Busulfan (4mg/kg/day 4 days) and hi
- Page 246 and 247:
6. Reiffers J, Trouette R, Marit G,
- Page 248 and 249:
RESULTS Hematological recovery to >
- Page 250 and 251:
AUTOLOGOUS PHILADELPHIA (PH) CHROMO
- Page 252 and 253:
stage. However, the clinical result
- Page 255 and 256:
HIGH DOSE NITROSUREA FOLLOWED BY AB
- Page 257 and 258:
Lung complications were observed 22
- Page 259 and 260:
eceived 800mg/m 2 . 7 patients rece
- Page 261:
Table 1: Extrahematological toxicit
- Page 265 and 266:
INFLUENCE OF MINIMAL TUMOR CONTAMIN
- Page 267 and 268:
patients. Not surprisingly the PSCT
- Page 269 and 270:
THE RECOMBINANT HUMAN LIGAND FOR C-
- Page 271 and 272:
a significant increase in the numbe
- Page 273 and 274:
15. Molineux G, Pojda Z, et al: A c
- Page 275 and 276:
It was the objective of our study t
- Page 277 and 278:
Interestingly, patients autografted
- Page 279 and 280:
CR/PR Relapse 1—1 Chemotherapy Tr
- Page 281 and 282:
EFFECTS OF TWO SCHEDULES OF ADMINIS
- Page 283 and 284:
cells because of the bad haematolog
- Page 285 and 286:
sion in this arm. The evolution of
- Page 287 and 288:
Table 2. PBSC harvest. arm A arm 6
- Page 289:
Summaries
- Page 292 and 293:
R. Harousseau reviewed the results
- Page 294 and 295:
- as far as relapses are concerned:
- Page 296 and 297:
PHASE III STUDIES There are a very
- Page 298 and 299:
INDICATIONS FOR AUTOLOGOUS BONE MAR
- Page 300 and 301:
ies of ASCT in first complete remis
- Page 302 and 303:
Karel A. Dicke, Arlington Cancer Ce
- Page 304 and 305:
Chris Poynton, Department of Hemato